Table 1.
Recipient baseline characteristics stratified by survival
| Variable | <1 year survival | 1–10 year survival | >10 year survival | p-value |
|---|---|---|---|---|
| (n=964) | (n=2,843) | (n=1,364) | ||
| Male sex | 590 (61.2%) | 1,660 (58.4%) | 777 (57.0%) | 0.120 |
| Age (years, median, IQR) | 59 (51–64) | 58 (49–63) | 55 (45–61) | <0.001 |
| BMI (kg/m2, median, IQR) | 25.6 (21.6–28.7) | 25.3 (21.5–28.5) | 24.7 (20.7–28.1) | 0.001 |
| Donor-recipient pTLC ratio (median, IQR) | 1.02 (0.89–1.16) | 1.03 (0.91–1.17) | 1.03 (0.91–1.16) | 0.133 |
| Race/Ethnicity | 0.719 | |||
| White | 820 (85.1%) | 2,416 (85.0%) | 1,162 (85.2%) | |
| Black | 74 (7.7%) | 244 (8.6%) | 120 (8.8%) | |
| Hispanic | 47 (4.9%) | 131 (4.6%) | 62 (4.5%) | |
| Other | 23 (2.4%) | 52 (1.8%) | 20 (1.5%) | |
| Diabetes | 170 (17.7%) | 475 (16.7%) | 221 (16.2%) | 0.636 |
| Malignancy | 68 (7.3%) | 168 (6.0%) | 59 (4.5%) | 0.015 |
| Diagnosis group | <0.001 | |||
| A | 325 (33.7%) | 1,124 (39.5%) | 500 (36.7%) | |
| B | 34 (3.5%) | 75 (2.6%) | 39 (2.9%) | |
| C | 100 (10.4%) | 347 (12.2%) | 222 (16.3%) | |
| D | 505 (52.4%) | 1,297 (45.6%) | 603 (44.2%) | |
| Creatinine (mg/dL, median, IQR) | 0.9 (0.7–1.1) | 0.8 (0.7–1.0) | 0.8 (0.7–1.0) | <0.001 |
| Total bilirubin (mg/dL, median, IQR) | 0.5 (0.3–0.8) | 0.5 (0.3–0.7) | 0.5 (0.3–0.7) | <0.001 |
| Pre-transplant status | <0.001 | |||
| Intensive care unit | 157 (16.3%) | 157 (5.5%) | 63 (4.6%) | |
| Hospitalized (non-ICU) | 89 (9.2%) | 198 (7.0%) | 86 (6.3%) | |
| Not hospitalized | 718 (74.5%) | 2,488 (87.5%) | 1,215 (89.1%) | |
| IV antibiotics in two weeks before transplant | 115 (12.5%) | 268 (9.8%) | 153 (11.6%) | 0.039 |
| Ventilator support at transplant | 89 (9.2%) | 112 (3.9%) | 51 (3.7%) | <0.001 |
| ECMO support at transplant | 23 (2.4%) | 11 (0.4%) | 6 (0.4%) | <0.001 |
| Lung allocation score (LAS, median, IQR) | 39.3 (34.5–49.0) | 37.7 (33.7–44.4) | 37.7 (33.8–45.0) | <0.001 |
| Days on waitlist (median, IQR) | 81(26–263) | 80 (24–253) | 87 (25–293) | 0.349 |
| Single lung transplant | 375 (38.9%) | 1,210 (42.6%) | 352 (25.8%) | <0.001 |
| HLA match | 0.624 | |||
| 0 antigen match | 177 (22.0%) | 541 (22.7%) | 233 (20.2%) | |
| 1 antigen match | 306 (38.0%) | 876 (36.7%) | 441 (38.2%) | |
| 2 antigen match | 202 (25.1%) | 631 (26.5%) | 301 (26.1%) | |
| 3+ antigen match | 120 (14.9%) | 337 (14.1%) | 180 (15.6%) | |
| Center annual lung transplant volume (median, IQR) | 28 (17–45) | 30 (22–45) | 30 (22–48) | <0.001 |
IQR, interquartile range; BMI, body mass index; pTLC, predicted total lung capacity; ICU, intensive care unit; ECMO, extracorporeal membrane oxygenation; HLA, human leukocyte antigen